ANTICORPS MONOCLONAUX HUMAINS POUR MORT PROGRAMMÉE 1 (PD-1) ET PROCÉDÉS DE TRAITEMENT DU CANCER À L'AIDE D'ANTICORPS ANTI-PD-1 SEULS OU COMBINÉS À D'AUTRES FORMULATIONS IMMUNOTHÉRAPEUTIQUES
E. R. Squibb & Sons, L.L.C.;ONO Pharmaceutical Co., Ltd.
发明人:
申请号：
EP19151041.1
公开号：
EP3530736A2
申请日:
2006.05.02
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
